FDA Approves Boruzu (bortezomib) Ready-to-Use Injection for Multiple Myeloma and Mantle Cell Lymphoma

BRIDGEWATER, N.J.–(BUSINESS WIRE) September 5, 2024 — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) and Shilpa Medicare Limited (“Shilpa”) announced U.S. Food and Drug Administration…Original Article